The CEO and co-founder of Theranica discussed the migraine treatment device’s mechanism of action and its successes in reducing medication overuse headache.
"That is a drug-free, safe alternative that provides both patients and providers with another way to treat migraine. Effective, safe, and without worrying about [inducing medication overuse headache]."
With its impending roll out coming in 2020, the introduction of the Nerivio Migra device has the potential to make an impact on the treatment of migraine, according to Alon Ironi, CEO and co-founder of the device’s manufacturer, Theranica.
NeurologyLive® spoke with Ironi at the 2019 American Headache Society (AHS) Annual Meeting, July 11-14, 2019, in Philadelphia, Pennsylvania, about the smartphone-controlled electroceutical device, which was granted De Novo clearance for the use of non-invasive neuromodulation for the acute treatment of migraine with or without aura in adults who do not have chronic migraine.
Ironi shared insights into the therapy’s mechanism of action, which triggers an endogenous mechanism in the brain stem that ultimately results in conditioned pain modulation. He also spoke to the clinical evidence that the device has shown thus far, as well as some recent findings on its impact on acute medication overuse.
For more coverage of AHS 2019, click here.
1. FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device [press release]. Netanya, Israel: Theranica; May 28, 2019. prnewswire.com/news-releases/fda-grants-theranica-de-novo-to-market-first-smartphone-controlled--acute-migraine-relief-wearable-device-300857281.html. Accessed July 31, 2019.
2. Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine [press release]. Scottsdale, Arizona: Theranica Bio-Electronics; November 15, 2018. prnewswire.com/news-releases/theranica-announces-results-from-pivotal-study-of-device-for-treating-acute-migraine-832012898.html. Accessed July 31, 2019.